NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.20 +0.21 (+0.27%) GOLD FUTURES
2,316.60 -5.70 (-0.25%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,140.01 -1,209.95 (-2.40%)
AVDL Jan 2025 12.500 call
| Previous close | 6.80 |
| Open | 5.46 |
| Bid | 4.90 |
| Ask | 5.80 |
| Strike | 12.50 |
| Expiry date | 2025-01-17 |
| Day's range | 5.46 - 5.46 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.66k |
GuruFocus.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
Insight into Avadel Pharmaceuticals' Q1 Financial Performance and Strategic Updates
GlobeNewswireAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 0
- GlobeNewswire
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada
